Chart, page-2654

BARD1 will engage with leading gynecological/surgical oncologists, research clinicians and biostatisticians

to prepare its clinical testing plan for early detection of both breast and ovarian cancers and to initiate

prospective collection of biospecimens to enable rapid commencement of clinical studies in 2019 upon the

successful transfer of the research-grade BARD1 autoantibody test to the Luminex instrumentation. BARD1 will continue to advance discussions with its potential corporate and

financial partners to build the Company and speed development and commercialisation of its diagnostic

assets to maximize value for shareholders.